Partnering Opportunities
Leiden University and Leiden University Medical Center (LUMC) are seeking commercial partners for collaborative development or licensing of the below mentioned technologies.
Filter categories
-
Service Offered: High-Throughput Profiling of Protein N-Glycosylation Employing Linkage-Specific Sialic Acid Esterfication
The team of Professor Manfred Wuhrer at Leiden University Medical Center (LUMC), have developed a rapid, robust and linkage-specific high-throughput method for sialic acid stabilization and analysis of complex glycoprotein mixtures such as human plasma N-glycome. -
Service Offered: Cell Model of Immune Responses
Scientists at Leiden University Medical Center (LUMC), have developed a dendritic cell culture system as a read-out of the immune response and as a replacement for animal testing. -
Tumor Associated Carbohydrate Antigens as Targets for Colorectal Cancer Immunotherapy
The present invention relates to a novel method to identify highly specific tumor associated carbohydrate antigens (TACAs) derived from colorectal cancer (CRC) tissue. -
Immunomodulatory Capacity and Therapeutic Potential of S.mansoni-Derived Proteins in the Context of Immune Modulation, Asthma and/or Allergy
Proteomics analysis on several fractions was performed and identified a number of unique proteins of which some were highly abundant. Identification of unique Breg-inducing molecules may form interesting treatment targets for inflammatory diseases such as asthma or allergies. -
Cytotoxicity of Synthesized EPD (EPD-S), A Natural Sesquiterpene Lacton, and its Future Clinical Efficacy
The present invention is relating to a new anti-cancer drug, EPD-S. This drug shows on itself, as well as in combination with paclitaxel and cisplatin, strong cytotoxicity against ovarian cancer and other cancer types. -
Targeting ligand-bound (solid-phase) C1q
We have recently developed recombinant fully human antibodies that strongly bind to C1q that is bound to its ligands (solid-phase) but does not bind to circulating C1q. -
Targeted Complement Inhibition
We have developed strategies to target complement inhibition to specific tissues / cells to achieve local complement inhibition while leaving the systemic complement pool available to fight infections and achieve homeostasis.